Propel(x) is a Franklin Templeton Evo Nexus Incubator Portfolio Company
This early-stage startup is working on next-generation immunotherapies. They have already received an accepted IND from the FDA in April 2023. This round is oversubscribed but an allocation has been made specifically for Propel(x) investors!
Join the pitch to get insights about:
The pitch will be followed by a Q&A round where investors can ask questions directly to the startup founders.As per regulations, these calls are for accredited investors only. You will have to register on Propel(x) to confirm your accredited status and risk profile.
If you are unable to attend this webinar, register anyway and you will have access to the recording at a later date. After submitting the form, you will be redirected to the Propel(x) investing app to complete your registration.Disclosure: Private Placements are a high-risk investment. An investment in such offerings is speculative and an investor could experience an entire loss of principal. Past performance may not be indicative of future results. Private investments are highly illiquid and risky and are not suitable for all investors. Investments in early-stage private companies should only be part of your overall investment portfolio.
Propel(x) is a Franklin Templeton Evo Nexus Incubator Portfolio Company
This site is operated by Propel(x) Inc. (“Propel(x)”), which is not a registered broker dealer. Propel(x) does not give investment advice, endorsement, analysis or recommendations with respect to any securities. All securities posted here are being offered by, and all information included on this site is the responsibility of the issuer of such securities. Propel(x) has not taken steps to verify the adequacy, accuracy, or completeness of the information. Neither Propel(x) nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind related to the adequacy, accuracy or completeness of any information on this site or the use of information on this site. By accessing this site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.
This Website is intended solely for accredited investors. Private Investments are highly risky and are not suitable for all investors. Investments in early-stage private companies should only be part of your overall investment portfolio. Furthermore, the allocation to this asset sub-class may be best fulfilled through a balanced portfolio of diversified startups. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest. There is no guarantee that an investment will be profitable. All investments bear the risk of partial or complete loss of capital. Please review risk factors for investments on Propel(x) here.
Certain opportunities posted on the platform and so designated are advised by Planck Fund Management Corporation (“PFMC”), an affiliate of Propel(x), located at 1 Franklin Parkway, Bldg # 930/1 – Fintech Suite, San Mateo CA 94403. PFMC does not make investment recommendations and no communication, through this website or in any other medium should be construed as a recommendation for any security offered on or off this investment platform.
Brokerage products and services offered by Hubble Investments, Member FINRA – https://www.finra.org/about and SIPC https://www.sipc.org/ an
©2023 Propel(x). All rights reserved. Various trademarks held by their respective owners.
